A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

This clinical trial is studying a new way to give a drug called blinatumomab to children under age 12 who have B-cell acute lymphoblastic leukemia (B-ALL). While this drug is often given as a continuous infusion through a central line, this study tests an injection given just under the skin, known as a subcutaneous injection. Blinatumomab works by acting as a bridge between your child’s immune cells and the cancer cells, helping the immune system recognize and destroy the leukemia.

The study is open to children whose B-ALL has returned (relapsed) or did not respond to previous treatments, including those who may still have a small amount of disease called minimal residual disease. To join, your child must have a certain level of physical activity and no history of severe neurological issues like seizures or strokes. Children who have had a bone marrow transplant must be at least 12 weeks past their procedure. Because of how the drug works, children with Down syndrome or active autoimmune diseases are not eligible for this specific study.

If your child participates, they will receive injections in cycles lasting 35 days each, for up to five cycles. Before enrolling, you should talk with your doctor about your child’s full medical history, especially any past neurological events or previous immune-based therapies, to see if this approach is a safe option for them.